Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Five Residues in the Apical Loop of the Respiratory Syncytial Virus Fusion Protein F2 Subunit Are Critical for Its Fusion Activity.

Hicks SN, Chaiwatpongsakorn S, Costello HM, McLellan JS, Ray W, Peeples ME.

J Virol. 2018 Jul 17;92(15). pii: e00621-18. doi: 10.1128/JVI.00621-18. Print 2018 Aug 1.

2.

Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection.

Capella C, Chaiwatpongsakorn S, Gorrell E, Risch ZA, Ye F, Mertz SE, Johnson SM, Moore-Clingenpeel M, Ramilo O, Mejias A, Peeples ME.

J Infect Dis. 2017 Dec 12;216(11):1398-1406. doi: 10.1093/infdis/jix489.

3.

Molecular mechanism of respiratory syncytial virus fusion inhibitors.

Battles MB, Langedijk JP, Furmanova-Hollenstein P, Chaiwatpongsakorn S, Costello HM, Kwanten L, Vranckx L, Vink P, Jaensch S, Jonckers TH, Koul A, Arnoult E, Peeples ME, Roymans D, McLellan JS.

Nat Chem Biol. 2016 Feb;12(2):87-93. doi: 10.1038/nchembio.1982. Epub 2015 Dec 7.

4.

Targeting RSV with vaccines and small molecule drugs.

Costello HM, Ray WC, Chaiwatpongsakorn S, Peeples ME.

Infect Disord Drug Targets. 2012 Apr;12(2):110-28. Review.

5.

Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer.

Chaiwatpongsakorn S, Epand RF, Collins PL, Epand RM, Peeples ME.

J Virol. 2011 Apr;85(8):3968-77. doi: 10.1128/JVI.01813-10. Epub 2011 Feb 9.

Supplemental Content

Loading ...
Support Center